Look, if you’ve been riding the S&P 500 via SPY or VOO for the last few years, you’ve probably felt pretty smart. The index has been on a tear, largely thanks to a handful of mega-cap names. But that outperformance comes with a quiet risk a lot of people gloss over: concentration. Let’s break down the regular (market-cap weighted) S&P 500 versus its equal-weight cousin, why the top-heavy nature of the main index can bite, and how you can soften that risk with some straightforward defensive ETFs.
Cap-Weighted S&P 500 vs Equal-Weight: Same Stocks, Very Different Bets
Both versions hold basically the same ~500 large-cap U.S. companies. That’s where the similarity ends.
The classic S&P 500 is market-cap weighted. The bigger the company, the bigger its influence. As of recent data (around September 2026), the top 10 stocks make up roughly 37–39% of the index. The largest single name (often Nvidia lately) can sit around 8%. Tech and related mega-caps dominate. When those leaders run, the whole index flies. When they stumble, the index feels it hard.
The equal-weight S&P 500 (tracked by RSP) resets every stock to roughly the same weight (~0.2%) at each quarterly rebalance. No stock gets to dominate. The top 10 end up around 2–3% combined. You get more exposure to the smaller end of the large-cap universe, more sector balance (less tech overweight, more industrials, financials, materials, etc.), and a built-in “sell high, buy low” effect from the rebalancing.
Key contrasts:
Concentration**: Cap-weighted can feel like a mega-cap growth fund in disguise. Equal-weight is much closer to true equal diversification across the 500.
Performance style**: Cap-weighted has crushed it in the mega-cap/AI-driven years. Equal-weight tends to do better when market breadth improves (more stocks participating) or when value/smaller large-caps lead. Over very long periods equal-weight has sometimes edged ahead, but the last decade or so has clearly favored the cap-weighted version.
Costs & mechanics**: Equal-weight has higher turnover (and a slightly higher expense ratio, ~0.20% for RSP vs under 0.10% for the big SPY/VOO), so it’s not free. It can also show a bit more volatility in some periods because you’re overweighting the smaller names within the index.
What you’re really owning**: Cap-weighted is a bet that the biggest winners keep winning. Equal-weight is a bet on broader participation and mean-reversion.
Neither is “better” in all markets. They’re different tools.
Why Index Concentration Is a Real Risk
When 10 stocks control nearly 40% of your “diversified” large-cap index, you’re not as diversified as the 500 number suggests. A few things can go wrong:
Valuation compression or earnings misses at the top can drag the whole index down even if the other 490 stocks are fine.
Sector shocks (tech regulation, AI hype cooling, interest-rate sensitivity in growth stocks) hit harder.
Liquidity and sentiment can get concentrated too—everyone is piled into the same names.
You lose some of the classic diversification benefit that indexing is supposed to provide.
History shows that extreme concentration periods have often been followed by stretches where the rest of the market catches up or the leaders lag. It doesn’t mean the mega-caps are doomed tomorrow, but it does mean the risk/reward of pure cap-weighted exposure has shifted.
How to Hedge with Defensive ETFs
You don’t have to abandon the S&P 500. A common, practical approach is to keep a core position (maybe some mix of cap-weighted and equal-weight) and add targeted defensive sleeves that behave differently.
Healthcare (e.g., XLV)**: Classic defensive sector. Demand for drugs, devices, and care doesn’t disappear in a recession. Aging demographics are a long-term tailwind. It usually has lower beta than the broad market and can provide ballast when growth stocks get hit. It’s not zero-volatility, but it tends to hold up better in risk-off periods.
Energy (e.g., XLE)**: More cyclical than pure defensive, but it brings commodity exposure and can act as an inflation or geopolitical hedge. When oil prices rise or the broader market is worried about growth, energy often marches to its own drummer. It’s a useful diversifier against pure equity-market beta, especially if you’re heavy in tech/growth.
Dividend Aristocrats (e.g., NOBL)**: These are S&P 500 companies that have raised their dividends for at least 25 consecutive years. The index is equal-weighted and tilts toward quality, profitability, and more mature businesses (consumer staples, healthcare, industrials, etc.). You get income, a quality filter, and less reliance on pure growth stories. It tends to be less volatile than the broad market and provides a different factor exposure (quality + dividend growth).
How to use them practically:
You could run something like 60–70% core S&P exposure (split between SPY/VOO and RSP if you want to dial down concentration), then 10–15% healthcare, 5–10% energy, and 10–15% Dividend Aristocrats. Exact weights depend on your risk tolerance, time horizon, and views on the cycle. Rebalance periodically. The goal isn’t to eliminate risk—it’s to reduce the chance that a handful of mega-caps dictate your entire portfolio’s fate.
Equal-weight already helps with single-stock concentration. Layering in these defensive/specialized ETFs adds sector, factor, and behavioral diversification. You’re not trying to time the market perfectly; you’re just refusing to put all your eggs in the “mega-caps must keep winning forever” basket.
Bottom line: The regular S&P 500 is still a fantastic long-term vehicle, but its current concentration means it’s no longer a pure “own the market” bet. Equal-weight gives you a cleaner version of the same universe, and a modest allocation to healthcare, energy, and Dividend Aristocrats can smooth the ride without forcing you into complicated strategies. Diversification still works—sometimes you just have to work a little harder to get it.
Comments